Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 15/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13698551 | 0.85 | CHRM1 (0.50) | CHRM1CHRM5CHRM2CHRM4 | |
| SCHEMBL3453802 | 0.80 | KDM4E (0.51) | CHRM1 | |
| SCHEMBL13698554 | 0.78 | SLC6A9 (0.47) | CHRM1AOC3 | |
| SCHEMBL3453198 | 0.77 | HRH3 (0.48) | CHRM1CHRM5CHRM2CHRM4 | |
| SCHEMBL3453501 | 0.76 | ALDH1A1 (0.44) | CHRM1 | |
| SCHEMBL3604310 | 0.74 | ALDH1A1 (0.47) | CHRM1CHRM5CHRM2CHRM4 | |
| SCHEMBL3453746 | 0.74 | P2RY12 (0.48) | CHRM1CHRM5CHRM2CHRM4 | |
| SCHEMBL3454291 | 0.73 | PANK3 (0.49) | CHRM1 | |
| SCHEMBL5197445 | 0.73 | MAPT (0.42) | CHRM1CHRM5CHRM2CHRM4 | |
| SCHEMBL3453576 | 0.72 | HRH3 (0.51) | CHRM1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239873-A1 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | BLANCO MIGUEL GARCIA-GUZMAN | 2009-09-24 | — | — | US | disclosed |
| US-20090239873-A1 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | BLANCO MIGUEL GARCIA-GUZMAN | 2009-09-24 | — | — | US | disclosed |
| US-7563795-B2 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563795-B2 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239873-A1 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | CHRM1 6/4885CHRM5 2/4885CHRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.